COMMUNIQUÉS West-GlobeNewswire

Wright Medical Group N.V. to Host First Quarter 2019 Earnings Conference Call
09/04/2019
Tuesday, May 7, 2019 at 3:30 p.m. Central / 4:30 p.m. Eastern AMSTERDAM, The Netherlands, April 09, 2019 (GLOBE NEWSWIRE) -- Wright Medical Group N.V. (NASDAQ: WMGI) today announced that it will host a conference call [...]
Biohit GastroPanel® biomarkers validated as powerful predictors of gastric cancer risk in a multicenter study
09/04/2019
Press release Biohit Oyj 9 th April 2019 at 09.30 local time (EEST) Biohit GastroPanel ® innovation is the unique non-invasive diagnostic tool for examination of i) dyspeptic patients for exclusion or diagnosis of [...]
NANOBIOTIX RAISES APPROXIMATELY EUR 29.5 MILLION IN PLACEMENT OF ORDINARY NEW SHARES
09/04/2019
NANOBIOTIX RAISES APPROXIMATELY EUR 29.5 MILLION IN PLACEMENT OF ORDINARY NEW SHARES Funds raised through an accelerated bookbuild offering announced on April 8, 2019 Placement follows announcement of the first European [...]
NANOBIOTIX LEVE ENVIRON 29,5 MILLIONS D’EUROS DANS LE CADRE D’UN PLACEMENT D’ACTIONS ORDINAIRES NOUVELLES
09/04/2019
NANOBIOTIX LEVE ENVIRON 29,5 MILLIONS D’EUROS DANS LE CADRE D’UN PLACEMENT D’ACTIONS ORDINAIRES NOUVELLES Les fonds ont été levés par construction accélérée d’un livre d’ordre annoncé le 8 avril 2019 Le placement fait [...]
Biocartis Group NV: Invitation to Annual Shareholders' Meeting
09/04/2019
Invitation to Annual Shareholders' Meeting Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), has the honor to invite its shareholders, warrant [...]
Verona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate Ensifentrine
09/04/2019
Bolsters patent estate for lead development candidate and provides expiry dates out to 2035 LONDON, April 09, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical stage [...]
Neovacs announces the full results of its Phase IIb Clinical study of IFNalpha Kinoid in lupus - 13th International Lupus Congress 2019
09/04/2019
PRESS RELEASE · PRESS RELEASE · PRESS RELEASE N E OVACS ANNOUNCES THE FULL RESULTS OF ITS PHASE IIb CLINICAL STUDY OF IFN α KINO ID IN LUPUS, PRESENTED AT THE 13 th INTERNATIONAL LUPUS CONGRESS 2019 Paris and Boston, [...]
Néovacs annonce les résultats complets de son étude clinique de phase IIb avec l'IFNalpha Kinoïde dans le lupus - 13ème congrès International du Lupus
09/04/2019
COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE N É OVACS ANNONCE LES RÉSULTATS COMPLETS DE SON É TUDE CLINIQUE DE PHASE IIb AVEC L’IFN α KINO Ï DE DANS LE LUPUS, PRESENTÉS AU 13 ÈME CONGRÈS [...]
Diem Labs Donates $20,000 Including 25 Cents From All Products to Vitamin Angels for 25th Anniversary Year
08/04/2019
ANN ARBOR, Mich., April 08, 2019 (GLOBE NEWSWIRE) -- Diem Labs has committed $20,000 to Vitamin Angels this year and in honor of the charity’s 25 th anniversary will include as part of that donation 25 cents for each [...]
Chimerix Announces Management Updates
08/04/2019
Mike Sherman Appointed Chief Executive Officer and Mike Andriole Appointed Chief Business Officer DURHAM, N.C., April 08, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel [...]
Autolus Announces Proposed Public Offering in the United States
08/04/2019
LONDON, April 08, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it intends to [...]
Natus Medical to Hold 2019 First Quarter Financial Results Conference Call on April 25th
08/04/2019
PLEASANTON, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: BABY), a leading provider of medical devices and services, today announced that the Company will release its 2019 first quarter [...]
T2 Biosystems Reports Granting of Inducement Awards
08/04/2019
LEXINGTON, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare [...]
NGM Bio Announces Multiple Presentations at The International Liver Congress™ 2019
08/04/2019
SOUTH SAN FRANCISCO, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on harnessing powerful biology to develop transformative [...]
DBV Technologies Announces Closing of Global Offering
08/04/2019
Montrouge, France, April 8, 2019 DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the settlement and delivery [...]
DBV Technologies annonce la réalisation de son offre globale
08/04/2019
Montrouge, France, le 8 avril (22h30 CEST), 2019 DBV Technologies (la « Société ») (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT), société biopharmaceutique française, annonce ce jour le règlement [...]
Daré Bioscience, Inc. Announces Proposed Public Offering of Common Stock
08/04/2019
SAN DIEGO, April 08, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it intends to offer shares of its common stock in an underwritten public [...]
Homology Medicines Announces Proposed Public Offering of Common Stock
08/04/2019
BEDFORD, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, today announced that it intends to offer and sell, subject to market and other conditions, $125.0 [...]
Translate Bio Presents Preclinical Data Supporting MRT5201 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting
08/04/2019
-- MRT5201 was efficiently delivered to the liver of a mouse model of OTC deficiency -- -- Preclinical data demonstrated a single IV dose of MRT5201 was sufficient to protect against hyperammonemia for up to 4 weeks -- [...]

Pages